DBV Technologies (NASDAQ:DBVT) PT Raised to $7.00 at HC Wainwright

DBV Technologies (NASDAQ:DBVT) had its price objective raised by investment analysts at HC Wainwright from $5.00 to $7.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright also issued estimates for DBV Technologies’ FY2024 earnings at ($1.41) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.50) EPS.

DBVT has been the subject of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and set a $5.00 price target on shares of DBV Technologies in a research note on Tuesday, September 24th. StockNews.com started coverage on shares of DBV Technologies in a research report on Monday, October 21st. They set a “hold” rating on the stock.

DBV Technologies Stock Performance

Shares of DBVT opened at $0.87 on Thursday. DBV Technologies has a 52 week low of $0.50 and a 52 week high of $2.28. The company has a market capitalization of $83.61 million, a PE ratio of -1.03 and a beta of 0.67. The company’s 50 day moving average price is $0.77 and its 200 day moving average price is $0.96.

DBV Technologies (NASDAQ:DBVT) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08). DBV Technologies had a negative return on equity of 74.41% and a negative net margin of 638.21%. The company had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. During the same period last year, the company posted ($0.26) earnings per share. On average, equities analysts forecast that DBV Technologies will post -1.43 earnings per share for the current fiscal year.

Institutional Trading of DBV Technologies

A hedge fund recently raised its stake in DBV Technologies stock. Yiheng Capital Management L.P. increased its stake in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies makes up 0.2% of Yiheng Capital Management L.P.’s investment portfolio, making the stock its 15th largest holding. Yiheng Capital Management L.P. owned approximately 2.89% of DBV Technologies worth $4,172,000 as of its most recent filing with the SEC. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.